NewsBenzingaAdagene、肝転移を伴わないマイクロサテライト安定型大腸癌を対象としたムザストトゥグの第2相試験における患者登録完了を発表 Adagene、肝転移を伴わないマイクロサテライト安定型大腸癌を対象としたムザストトゥグの第2相試験における患者登録完了を発表 Benzinga 2026.11.09 12:20 (GMT+0) Open on Benzinga Other news Arthur Hayes: Bullish on ETH, ZEC, NEAR and VVV, Has Built Small- and Mid-Sized Positions Huang's Nvidia Return Odds Rebound to 11% on Kalshi Hackers Spread Crypto-Stealing Trojan via Fake GTA 6 PC Download Links Invesco's Stablecoin Reserve Fund Goes Live on Ethereum 7 Major US Banks Disclose XRP ETF Holdings in SEC Filings, Totaling About $29.4M Anthropic Requires Employees to Set Written Plans 30 Days in Advance to Sell Shares, to Prevent Insider Trading
Anthropic Requires Employees to Set Written Plans 30 Days in Advance to Sell Shares, to Prevent Insider Trading